Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.

Nvidia (NVDA) remains a strong buy, with earnings growth outpacing share price appreciation and valuation multiples ...

Oracle’s ORCL relationship with OpenAI has become a never-ending source of market angst, as the tie-in reminds many of questionable vendor-financing practices from the late 1990s. Tied to Oracle’s ...

Return on Intelligence gives CMOs three crucial advantages: ...

Gaming performance is strong too, obviously within reason. The 144Hz display sounds impressive, but most popular titles like ...

With bad loans shrinking & capital buffers stronger, urban co-op banks’ new umbrella body NUCFDC is now prioritising rollout ...

Nano Nuclear Energy Inc. (($NNE)) has held its Q4 earnings call. Read on for the main highlights of the call. Nano Nuclear Energy Earnings Call ...

Apyx Medical's latest narrative update keeps the fair value estimate steady at $6.00 per share, but fine tunes the underlying assumptions as analysts reassess risk and growth around the AYON platform.

New electric cars from unexpected quarters and some defiantly old-school machines make next year an enticing one for car fans ...

Air miles are becoming increasingly difficult to redeem as airline loyalty programmes tighten access, yet travellers can ...

This 10-year history shows that Oracle shares have commanded as high as 66% premium (September 2025) to Microsoft share to a 55% discount (November 2020), with a 10-year median of 28% discount. The ...

A maiden resource is a defining moment and this article highlights ASX explorers aiming to unveil theirs in 2026.